These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17713053)

  • 1. [Combination therapy with oral antidiabetics].
    MMW Fortschr Med; 2007 Jun; 149(25-26):52-3. PubMed ID: 17713053
    [No Abstract]   [Full Text] [Related]  

  • 2. [Insulin detemir compared with NPH insulin. No significant differences identified in the studies].
    Liedholm H; Linné AB
    Lakartidningen; 2006 May 3-9; 103(18):1417, 1419-22, 1424-6. PubMed ID: 16729454
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insulin therapy in type 2 diabetes].
    Hummel M
    MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-acting insulins in the treatment of type 2 diabetes: a hard choice].
    Liebl A
    MMW Fortschr Med; 2015 Apr; 157(7):65-8. PubMed ID: 26012462
    [No Abstract]   [Full Text] [Related]  

  • 5. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ; Clauson P; Pedersen CB; Kølendorf K
    J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH.
    Mandosi E; Fallarino M; Rossetti M; Gatti A; Morano S
    Diabetes Res Clin Pract; 2009 May; 84(2):e18-20. PubMed ID: 19297054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
    Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ; Derezinski T; Pedersen CB; Clauson P
    Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
    Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Starting insulin therapy in type 2 diabetes: lesson 1.
    McCall AL
    Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
    [No Abstract]   [Full Text] [Related]  

  • 15. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial.
    Lundby Christensen L; Almdal T; Boesgaard T; Breum L; Dunn E; Gade-Rasmussen B; Gluud C; Hedetoft C; Jarloev A; Jensen T; Krarup T; Johansen LB; Lund SS; Madsbad S; Mathiesen E; Moelvig J; Nielsen F; Perrild H; Pedersen O; Roeder M; Sneppen SB; Snorgaard O; Tarnow L; Thorsteinsson B; Vaag A; Vestergaard H; Wetterslev J; Wiinberg N;
    Diabetes Obes Metab; 2009 Apr; 11(4):315-22. PubMed ID: 19267709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
    Albright ES; Desmond R; Bell DS
    Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes.
    Schmid C; Krayenbühl P; Wiesli P
    Diabetologia; 2009 Dec; 52(12):2668-9. PubMed ID: 19774359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.